Key Highlights
- Cairn Surgical raises $4.5 million in Series A2 financing, led by Morningside Ventures.
- Funds will support U.S. pivotal trial completion and limited European launch of the Breast Cancer Locator (BCL™) System.
- The BCL System aims to improve the precision of breast cancer surgeries by offering detailed tumor localization.
Source: Business Wire
Notable Quotes
- “We are delighted to have the continued support of Morningside Ventures, who believes in our vision of improving both outcomes for breast cancer patients and the healthcare economics of breast cancer surgery.” — David Danielsen, CEO at Cairn Surgical
- “Cairn Surgical has been – and continues to be – a key medtech investment for us. We are excited about its potential to significantly improve patient care, as well as reduce costs to the healthcare system.” — Mick Sawka, Investment Advisor at Morningside Ventures
SoHC's Take
Cairn Surgical’s recent funding round, led by Morningside Ventures, highlights the growing recognition of their Breast Cancer Locator (BCL™) System’s potential to revolutionize breast cancer surgery. With a personalized, 3D-printed guide based on precise imaging, the BCL System promises to address a critical gap in breast-conserving surgeries, where current methods fail in accurately removing the entire tumor up to 20% of the time. This innovation not only has the potential to improve patient outcomes significantly but also to reduce healthcare costs by minimizing the need for additional surgeries. As the company moves forward with its U.S. pivotal trial and European market introduction, it is well-positioned to set a new standard in breast cancer treatment.
